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Background & Aims: High IgG levels are considered a hallmark of autoimmune hepatitis (AIH). A subgroup of patients with
AIH has IgG within the normal range despite evidence of clinical disease activity. The clinical significance of this biomarker
has not been explored.
Methods: In a European multicentre study we compared biochemical, clinical and histological features from patients with
AIH and normal IgG-values at diagnosis to an age- and sex-matched control group of patients with typical AIH presenting
with elevated IgG. Data were assessed at diagnosis, after 12 months of therapy and at last follow-up.
Results: Out of 1,318 patients with AIH, 130 (10%) had normal IgG at presentation. Histological and biochemical parameters at
diagnosis, as well as treatment response, showed no difference between groups. Stable remission off treatment was achieved
more commonly in the normal IgG group than in the typical AIH group (24 vs. 8%; p = 0.0012). Patients of the control group
not only had higher IgG levels (29.5 ± 5.8 vs. 12.5 ± 3.2 g/L; p <0.0001), but also a higher IgG/IgA ratio (9.3 ± 6.9 vs. 5.4 ± 2.4;
p <0.0001) at diagnosis. The IgG/IgA ratio only declined in patients with typical AIH and was no longer different between
groups after 12 months (6.3 ± 4.3 vs. 5.5 ± 2.2; p = 0.1), indicating a selective increase of IgG in typical AIH and its suppression
by immunosuppression. Autoantibody titres were higher in the typical AIH group, but not when controlled for IgG levels.
Conclusions: Compared to AIH with typical biochemical features, patients with normal IgG levels at diagnosis (i) show similar
biochemical, serological and histological features and comparable treatment response, (ii) appear to lack the selective
elevation of serum IgG levels observed in typical active AIH disease, (iii) may represent a subgroup with a higher chance of
successful drug withdrawal.
© 2020 Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL). This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Autoimmune hepatitis (AIH) is a chronic non-resolving disorder
of the immune system characterized by loss of immunological
tolerance against hepatocytes inducing chronic inflammatory
destruction of liver parenchyma.1,2 In keeping with other auto-
immune disorders, AIH predominately affects women at any age
and its onset may range from asymptomatic to acute presenta-
tion with liver failure.3,4 If left untreated, AIH is a devastatingKeywords: autoimmune hepatitis; immunoglobulin G; drug withdrawal; immuno-
globulins; hypergammaglobulinemia.
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Medical Centre Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg. Tel.: +1
929 395 6403.
E-mail address: der.hanneshartl@gmail.com (J. Hartl).disease, however, the first controlled trails demonstrated that
immunosuppression prolonged survival.5–7 Despite the outlook
generally being good for treated AIH,8–11 it is usually a chronic
disease and relapse after drug withdrawal occurs in the vast
majority of patients.12,13
The diagnosis of AIH is based on descriptive criteria
assembled in a scoring system first issued in 1993,14 revised in
1999,15 and proposed in a simplified manner for routine clinical
use in 2008.16 Selective elevation of serum IgG levels is
considered a characteristic feature of AIH which is found in up
to 85% of patients14–16 and therefore has found its way into
diagnostic scores.17–19 In fact, apart from characteristic auto-
antibodies, findings on liver histology and the exclusion of viral
hepatitis, elevated IgG levels are the diagnostic backbone in the
simplified diagnostic scoring system proposed by the IAIHG in
2008.19
Research articleMoreover, it has been demonstrated that elevated IgG levels
indicate ongoing inflammatory activity in treated AIH.20,21
Consequently, most recent practice guidelines have defined
complete biochemical remission as repeatedly normal serum
aminotransferases and IgG levels,2,22,23 which is now accepted as
major treatment goal in AIH.
It is estimated that about 15%14–16 of patients with AIH
present with IgG levels within the normal range. However, the
clinical characteristics at presentation and the treatment
response of patients who are lacking such a distinctive feature of
AIH, have never been explored in detail. Therefore, we compared
the biochemical, clinical and histological features of patients
with AIH and normal IgG-values at diagnosis to an age- and sex-
matched control group of patients with typical AIH presenting
with elevated IgG.Patients and methods
Patient population
This is a retrospective multicentre study including patients from
5 European high-volume centres: Hamburg (HH), London (LON),
Nijmegen (NIJ), Birmingham (BHAM), Larissa (LA).
Each centre was invited to include patients with AIH and
normal serum IgG levels at diagnosis (“normal IgG group”)
and a 1:1 age- and sex-matched control group of patients
with AIH presenting with elevated IgG at diagnosis. Patients
in the control AIH group are referred to as patients with
typical AIH (“typical AIH group”) throughout the manuscript,
since high serum IgG levels are considered a very distinctive
feature of AIH.
Only patients who had undergone a liver biopsy at diagnosis
and in whom autoantibody titres (anti-nuclear antibody [ANA],
smooth muscle antibody [SMA], liver kidney microsomal antigen
[LKM], anti-mitochondrial antibody [AMA]) at diagnosis were
available were considered eligible for this study. Each centre was
asked to report the total number of patients with AIH who
fulfilled these criteria.
The diagnosis of AIH relied on clinical, biochemical, sero-
logical and histopathological findings.2 In order to further
assure a valid diagnosis of AIH in patients with normal IgG, a
crude assessment of the revised original diagnostic score from
1999 was performed.18 Due to the retrospective study design,
no detailed information on alcohol intake nor on HLA DR3 and
DR4 was available. These factors were given zero points. In
patients in whom liver histology had been classified according
to the simplified score from 2008 as “typical AIH” or
“compatible with AIH” but in whom a more detailed specifi-
cation of histological criteria was not available, liver histology
was scored as follows: Patients with “typical AIH” were
given +4 points, since classification as “typical AIH” requires
interface hepatitis (+3) and rosettes (+1) as well as emper-
ipolesis; patients with “compatible AIH” were given +1
point,18,19 since it is unclear which characteristic histological
feature was present.
Patients with overlap with primary biliary cholangitis or
sclerosing cholangitis and with follow-up of less than 2 years
were not included.
Concomitant autoimmune diseases
The presence of the following concomitant autoimmune diseases
was assessed: rheumatoid arthritis, diabetes mellitus type 1,JHEP Reports 2020sicca syndrome, coeliac disease, scleroderma, thyroid disease,
multiple sclerosis, vitiligo, inflammatory bowel disease.
Biochemical parameters
Data on biochemical and serological parameters, outcome and
treatment were assessed at diagnosis, after 12 months under
immunosuppression and at last follow-up. The following
biochemical and serological markers were assessed: ANA, SMA,
LKM, AMA, anti-soluble liver antigen and anti-liver-pancreas
antibodies, g-globulin, IgG, IgM, IgA, alanine aminotransferase,
aspartate aminotransferase, alkaline phosphatase, gamma glu-
tamyltransferase, albumin, bilirubin, creatinine, platelet count
and international normalized ratio (INR).
Liver histology
Only patients in whom liver biopsy had been performed to
establish the diagnosis of AIH were included. Histological staging
and grading according to Desmet and Scheuer classification were
assessed.24 A more detailed histological work-up was hampered
by the retrospective, multicentre study design. Therefore, each
centre was asked to send liver specimens to a reference
pathologist (M.R.) Histological re-examination involved using
Ishak’s score,25 the METAVIR scoring system26 and simplified
criteria for AIH diagnosis.19 We assessed the presence of biliary
lesions (cholangitis, bile duct loss, ductular reaction, periductular
fibrosis), the presence of steatosis (if present we used the NAFLD
activity score27) and fibrosis according to Kleiner.28
The study has been approved by the local ethics committees.
Written informed consent was obtained from all participants.
Statistical analysis
Summary statistics for categorical variables are expressed as
numbers (percentages). Quantitative variables are described as
means with their standard deviations or as medians with their
range if not normally distributed. Depending on the distribution,
parametric and non-parametric tests including paired/unpaired t
test and Wilcoxon signed rank test were used to test for differ-
ences between groups.
Comparison of categorical data between groups was
performed using the chi-square test or fisher’s exact test as
appropriate. All p values were 2-tailed. P values <0.1 were
reported, the significance level was set at p <0.05. Statistical
analysis was performed with GraphPad PRIMS (GraphPad Prism)
Version 8.Results
Out of a total of 1,318 eligible patients with AIH, 130 patients
with normal IgG were identified. Hence, the overall proportion of
patients with AIH and normal IgG was 10% (130/1,250), and this
percentage was similar in all centres (London: 51/481 (10%),
Hamburg: 31/352 (9%), Larissa: 30/317 (10%), Birmingham: 9/89
(10%), Nijmegen: 9/79 (13%)).
In all patients with AIH and normal IgG, the crude assessment
of the original diagnostic score18 reached at least a score corre-
sponding to “probable diagnosis of AIH”, ranging from 10 to 19.
Each centre included an age- and sex-matched control group of
patients with elevated IgG (typical AIH). Median age at diagnosis
was 51 years (range: 17–85) and 77% were female. Concomitant
autoimmune diseases were equally common in both groups
(normal IgG group: 20% vs. typical AIH group: 23%).2vol. 2 j 100094
Table 1. Biochemical, histological and clinical features at diagnosis, after 12 months of treatment and at last follow-up.
Normal IgG group (n = 130) Typical AIH group (control group) (n = 130) p value (if <0.1)*
At diagnosis
Female 77% 77%
Age, years 51 (17-85) 51 (21-82)
AST, U/L 590 ± 229 (529) 564 ± 345 (534)
ALT, U/L 701 ± 448 (265) 688 ± 523 (480)
ALP, U/L 193 ± 159 (143) 185 ± 120 (154)
Albumin, g/L 37 ± 11.9 (35) 35 ± 6.8 (35)
INR 1.2 ± 0.2 (1.2) 1.4 ± 1.1 (1.2)
Platelet count Mrd/L 228 ± 89 (210) 208 ± 83 (200)
Concomitant autoimmune disease** 23% 20%
Histological staging*** 2.3 ± 1.3 (2) 2.3 ± 1.2 (2)
Histological grading*** 3.0 ± 0.9 (3) 3.0 ± 1.0 (3)
Severe fibrosis (>2) 50% 50%
Liver cirrhosis 20% 20%
After 12 months of treatment
AST, U/L 36 ± 18 (28) 32 ± 23 (30)
ALT, U/L 45 ± 31 (28) 34 ± 27 (25)
Normal transaminases 75% 75%
At last follow-up
AST, U/L 29 ± 15 (24) 29 ± 13 (25)
ALT, U/L 28 ± 13 (22) 28 ± 14 (21)
Normal transaminases 77% 84%
Immunosuppressive treatment 76% 92% 0.0012
Follow-up, years 7.4 (2-10) 8.4 (2-15)
Adverse outcome 2 3
Mean values are presented with median in brackets.
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; INR, international normalized ratio.
* Continuous variables were compared using Wilcoxon singed rank rest. Fisher’s exact was used for comparing percentages.
** Rheumatoid arthritis, diabetes mellitus type 1, sicca syndrome, coeliac disease, scleroderma, thyroid disease, multiple sclerosis, vitiligo, inflammatory bowel disease.
*** According to Desmet and Scheuer classification.24Clinical characteristics of patients with AIH and normal IgG,
and of the control group, are displayed in Table 1.
Patient characteristics at diagnosis
Immunoglobulins
At diagnosis, average serum IgG levels were 12.5 ± 3.2 g/L in the
“normal IgG group” and 29.5 ± 5.8 g/L (p <0.0001) in patients
with typical AIH. Serum IgG levels decreased from 29.5 ± 5.8 g/L
to 13.6 ± 4.9 g/L (−55 ± 24%) within the first 12 months of
treatment in patients with typical AIH. Interestingly, patients
with normal IgG at diagnosis also showed a significant drop of
IgG within the normal range (Fig. 1). In these patients, IgG
declined from 12.5 ± 3.2 g/L to 9.7 ± 3.2 g/L within 12 months,
which corresponds to an average decrease of −22 ± 16% from
baseline (p <0.0001). A decrease of IgG within the normal range
could be observed in virtually all patients and IgG levels
remained lower than in the “typical AIH group” throughout the
study (p <0.0001) (Table 2).
Immunoglobulin A levels were available in 95 (73%) patients
with normal IgG and in 107 patients (82%) with typical AIH.
Patients with normal IgG at diagnosis had not only a lower
IgG, but also lower IgA-levels (at diagnosis: 3.9 ± 2.1 g/L vs. 2.8 ±
0.8 g/L, p <0.0001) (Table 2). Moreover, a significant but similar
drop of IgA could be observed in the “typical AIH group”
(−29 ± 18%) as well as in the “normal IgG group” (−22 ± 17%)
within the first 12 months of immunosuppression (Table 2).
Since both IgG and IgAwere higher in the “typical AIH group”,
we compared the IgG/IgA ratio in order to unveil a selective IgG
elevation, which is considered a serological hallmark of AIH.
Patients with typical AIH had a significantly higher IgG/IgA ratio
at diagnosis than patients in the “normal IgG group” (9.3 ± 3.6 vs.
5.4 ± 2.8, p <0.00001) (Table 2). Moreover, while the IgG/IgA ratioJHEP Reports 2020remained stable in patients with normal IgG during follow-up
(p = 0.47), it decreased in patients with typical AIH. On month
12 (typical AIH group: 6.3 ± 4.2 vs. normal IgG group 5.5 ± 2.2;
p = 0.1) and at the end of follow-up (6.6 ± 4.3 vs. 6.3 ± 3.4), the
IgG/IgA ratio was no longer different between groups (Table 2).
These findings underline the selective elevation of IgG in typical
AIH, while IgG and IgA dropped to the same extent in the
“normal IgG group”.
Immunoglobulin M levels were available in 95 (73%) patients
with normal IgG and in 107 patients (82%) with typical AIH. In
both groups, IgM levels showed a slight decrease upon immu-
nosuppression (Fig. 1C). However, in contrast to IgG and IgA, IgM
levels were not significantly different between the normal IgG
and typical AIH group. Consequently, the IgG/IgM ratio was
higher in the typical AIH group at diagnosis and during follow-up
(p <0.001), and moreover, the IgG/IgM ratio decreased in both
patients with typical AIH (p <0.0001) and patients with normal
IgG at diagnosis (p = 0.02) (Fig. 1E).
Hence, while the hypergammaglobulinemia typically seen in
AIH is predominantly attributable to IgG, IgA but not IgM also
seems to contribute.
Immunoglobulin levels at diagnosis and during follow-up are
displayed in Table 2 and Fig. 1.
Since some centres measure gamma-globulins instead of/in
addition to IgG, we also aimed to compare gamma-globulin levels
between groups. Gamma-globulins were only routinely assessed
by 2/5 participating centres (UKE and LA). In addition, themode of
measurement was different between centres. Gamma-globulins
at diagnosis and during follow-up were available in 50 patients
of the “normal IgG group” and 50 patients of the “typical AIH
group”. Despite IgG levels within the normal range, 14 (28%) pa-
tients of the “normal IgG group” had elevated gamma-globulins at3vol. 2 j 100094
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Fig. 1. Immunoglobulin levels at diagnosis, after 12 months of treatment and at last follow-up. (A) IgG, (B) IgA, and (C) IgM levels, as well as (D) IgG/IgA ratio
and (E) IgG/IgM ratio were compared betweein AIH with normal IgG at diagnosis and typicial AIH with elevated IgG. ***p <0.0001, **p <0.001, *p <0.05. AIH,
autoimmune hepatitis.
Research articlediagnosis. However, in those patients, gamma-globulins were
only slightly above the upper range of normal (<21% [normal
range: <18.8%] or <3.5 g/L [<3.2 g/L]). In contrast, all patients
within the “typical AIH group” had considerably elevated gamma-
globulins (range 24-37% or 3.5–6.6 g/L).
Autoantibodies
Median ANA and SMA titres in the “typical AIH group”were twice
as high as in patients with normal IgG at diagnosis (ANA 1:160
(range 1:40–1:5,120) vs.1:80 (1:40–1:1,280), p = 0.001; SMA 1:80
(range 1:20–1:5,120) vs. 1:40 (1:20–1:2,560), p <0.0001). How-
ever, IgG levels at diagnosis were also 2-fold higher in the control
group than in patients with normal IgG (29.5 ± 5.8 g/L vs.12.5 ± 3.2
g/L); correcting for this factor, ANA and SMA levels were similar
between groups. The higher IgG levels in the control group may
also explainwhy ANA and SMA could be detectedmore frequently
in the control group (ANA: 84% vs. 70%, p = 0.012; SMA: 70% vs.
50%, p = 0.0015). These results suggest that lower cut-offs for
autoantibodies should be considered in patients without elevated
IgG levels at presentation.
Histological parameters
Average fibrosis stage (2.3 ± 1.2 vs. 2.3 ± 1.3) and grade (3.0 ± 0.9
vs. 3.0 ± 23) according to Desmet and Scheuer classificationJHEP Reports 2020were not different between patients with normal IgG and
typical AIH at the time of diagnosis (Fig. 2). Moreover, patients
with severe fibrosis (fibrosis stage >−3) or cirrhosis at diagnosis
were equally distributed between groups (50%, and 20%,
respectively).
Liver histology was available for a detailed re-assessment by a
reference pathologist in 46 patients of the normal IgG group and
in 20 patients with typical AIH.
In patients with normal IgG at diagnosis, re-assessment ac-
cording to the simplified diagnostic criteria revealed histological
features atypical for the diagnosis of AIH in only a single patient
and this patient was consequently not included in this study.
In all other patients, liver histology was classified as typical
(76%) or compatible (22%) with AIH (Fig. 2). Interface hepatitis,
hepatocyte rosettes and emperipolesis were observed in 93%,
91%, and 78%, respectively. All liver specimens of the control
group were classified as typical (80%) or compatible (20%) with
AIH (Fig. 2).
Inflammatory activity according to Ishak’s modified activity
index at diagnosis did not differ between groups (typical AIH
group: 11 (median) vs. normal IgG: 11), and there was no
difference in components of the METAVIR system (Table S1).
Biliary lesions were frequently observed in both study groups,
but generally minimal and focal. While steatosis was seen in4vol. 2 j 100094
Table 2. Serum immunoglobulin levels at diagnosis, after 12 months of treatment and at last follow-up.
Normal IgG group (n = 130) Control group (typical AIH) (n = 130) p value (if <0.1)*
At diagnosis
IgG 12.5 ± 3.2 (12.8) 29.5 ± 5.8 (25.9) <0.00001
IgA 2.8 ± 0.8 (2.4) 3.9 ± 2.1 (3.4) 0.000025
IgM 1.64 ± 0.3 (1.5) 1.8 ± 0.3 (1.6)
IgG/IgA 5.4 ± 2.8 (5.0) 9.3 ± 3.6 (7.9) <0.00001
IgG/IgM 11.3 ± 5.9 (9.0) 20.9 ± 16.2 (16.9) <0.00001
ANA (>−1:40) 70% 84% 0.012
SMA (>−1:40) 70% 50% 0.0015
ANA, titre 1:80 (1:40-1:1,280) 1:160 (1:40-1:5,120)
SMA, titre 1:80 (1:20-1:2,560) 1:40 (1:20-1:5120)
Anti-SLA/LP (>−20 units/ml)** 17% 13%
LKM 6% 3%
At 12 months of treatment
IgG 9.7 ± 3.2 (9.8) 13.6 ± 4.9 (13.1) <0.00001
IgA 2.1 ± 0.6 (1.9) 2.6 ± 0.8 (2.5) 0.0045
IgM 1.32 ± 0.2 (1.1) 2.0 ± 0.4 (1.9)
IgG/IgA 5.5 ± 2.2 (5.2) 6.3 ± 4.2 (5.4) 0.094
IgG/IgM 10.3 ± 6.2 (8.4) 13.1 ± 6.5 (11.1) 0.006
At last follow-up
IgG 9.9 ± 3.0 (9.8) 13.4 ± 4.7 (12.6) <0.00001
IgA 2.1 ± 1.1 (1.9) 2.5 ± 0.98 (2.4) 0.013
IgM 1.3 (1.1) 1.4 (1.2)
IgG/IgA 6.3 ± 3.4 (5.3) 6.6 ± 4.3 (5.6)
IgG/IgM 11.4 ± 5.3 (9.0) 13.8 ± 5.9 (12.8) 0.05
Mean values are presented with median in brackets.
AIH, autoimmune hepatitis; AMA, anti-mitochondrial antibody; ANA, anti-nuclear antibody; Anti-SLA/LP, anti-soluble liver antigen and anti-liver-pancreas antibodies; LKM,
liver kidney microsomal antigen; SMA, smooth muscle antibody.
* Continuous variables were compared using Wilcoxon singed rank rest. Fisher’s exact was used for comparing percentages.
** Anti-SLA/LP antibodies were available in 85% of patients with normal IgG, and in 90% of patients with typical AIH.
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Fig. 2. Liver histology at the time of diagnosis. (A) Histological staging and
grading according to Desmet and Scheuer classification. (B) Histological clas-
sification according to the simplified diagnostic scoring system19 of liver
biopsies that were re-assessed by a reference pathologist.
JHEP Reports 2020one-fifth of patients in both groups, the degree of steatosis was
generally mild and only a single patient with normal IgG was
classified as AIH with non-alcoholic steatohepatitis.
A summary of the detailed histological assessment of
re-examined liver specimens is given in Table S1.
Biochemical parameters and treatment response
Except for IgG, no difference in biochemical markers could be
observed at diagnosis, after 12 months of immunosuppression or
at last follow-up. In fact, serum aminotransferases, biochemical
parameters of cholestasis, albumin and INR were almost iden-
tical in both groups (Table 1).
Average serum aminotransferases after 12 months of treat-
ment were 36 ± 18 U/L and 32 ± 23 U/L in patients with
normal IgG and in classical AIH, respectively. Moreover, the
proportion of patients with normalized serum aminotransfer-
ases was not significantly different between groups (at last
follow-up: “normal IgG group”: 76% vs. “typical AIH group”: 84%,
p = 0.16).
All patients received prednisolone to induce remission.
Median steroid dosage at diagnosis was 40 mg/d in both groups.
In 23% (normal IgG) vs. 20% (control group) of patients, pred-
nisolone could be tapered off within the first 12 months, while
26% vs. 30% required dual immunosuppressive treatment on the
long-term (usually steroids/azathioprine or steroids/mycophe-
nolate mofetil) to maintain biochemical remission. Taken
together, these findings indicate that there was no difference in
treatment response in patients with normal IgG at diagnosis and
those of the control AIH group.
We next assessed whether lower immunoglobulin levels
reflect different success rates in inducing immunological toler-
ance. At last follow-up, only 8% of patients in the control group5vol. 2 j 100094
Research articlewere in stable biochemical remission without immunosuppres-
sion, while in 24% of patients with normal IgG at diagnosis
immunosuppression had been successfully withdrawn
(p = 0.0012). It its well-known that most relapses occurs within
the first months after drug withdrawal,13 therefore, only patients
who remained in remission off treatment for at least 2 years
were considered in long-term remission after drug withdrawal.
In the cohort of patients with normal IgG, the 31 patients who
remained in remission without treatment were indistinguishable
from the 99 patients under immunosuppression at last follow-up
by age, sex, biochemical markers at diagnosis or after 12 months
of treatment. Moreover, on histological assessment there was no
difference in hepatic inflammation at diagnosis (grading: 3.1 ±1.4
[median: 3] vs. 3.0 ± 1.3 [median: 3]). Regarding fibrosis stage,
liver cirrhosis was less frequently present in patients with suc-
cessful drug withdrawal (4% vs. 25%, p = 0.026).
Likewise, no patient with successful drug withdrawal in the
typical AIH group had cirrhosis on liver histology, while cirrhosis
was present at diagnosis in 25% of patients who were under
immunosuppression at last-follow-up (p = 0.1). Interestingly, the
only significant difference between the 17 patients with suc-
cessful drug withdrawal and the rest of the control group were
lower IgG levels after 12 months of treatment (11.1 vs. 14.1 g/L,
p = 0.03), confirming previous reports29,30 and pointing to the
value of immunoglobulin levels as a marker of hepatic immune
tolerance in AIH.
All patients in this study with successful drug withdrawal had
AIH type I (presence of ANA and/or SMA).
Patient outcome
Follow-up time did not differ between study groups (normal IgG:
7.4 years, range 2–10, vs. control group: 8.4 years, range 2–15;
p = 0.82) and there was no difference in the severity of liver
disease at diagnosis as assessed by frequency of liver cirrhosis,
histological staging or grading, serum aminotransferases, and
INR (Table 1). During follow-up, an adverse event defined
as de novo signs of hepatic decompensation (ascites, hepatic
encephalopathy, variceal bleeding), liver transplantation or liver-
related death was documented in 2 patients in the “normal IgG
group” and in 3 patients in the control group. Thus, there was no
difference in outcome/prognosis between patients with normal
IgG concentration at diagnosis and those with typical AIH.Discussion
Selective elevation of serum IgG is a very distinctive feature of
AIH, which has been incorporated as a major criterion in diag-
nostic scores.17–19 Nevertheless, we found that every tenth
patient with AIH presented with normal IgG, which is in line
with previous reports.14–16 The clinical significance of this
finding has so far never been explored in detail.
This study highlights that patients with normal IgG are
indistinguishable from patients with typical AIH, based on the
frequency of concurrent immune diseases, laboratory indices,
histological features including grading and staging at diagnosis,
as well as treatment response. In fact, it was striking how similar
biochemical and histological parameters, as well as treatment
responses, were in both groups.
Patients with normal IgG at diagnosis might represent a
subtype with a higher chance of long-term remission after drug
withdrawal. Despite reports of relapse rates as high as 95% after
stopping immunosuppression,13 24% of patients with normal IgGJHEP Reports 2020at diagnosis were in stable biochemical remission off treatment
at last follow-up, while this was only the case in 8% of patients
with typical AIH. This finding is in line with a former report,
which observed that lower gamma-globulin levels at diagnosis
were associated with successful drug withdrawal.29 Moreover, in
the typical AIH group, those with stable remission off treatment
differed from those who were on immunosuppression at last
follow-up by lower IgG levels after 12 months of treatment.
Accordingly, it has been reported that IgG levels in month 6
of treatment were an independent predictor of maintenance
of remission after treatment withdrawal30 and low IgG (below
12 g/L) at the time of tapering off medication were predictive
of successful drug withdrawal.31 Thus, these results indicate
that low IgG might reflect success rates of inducing hepatic
immune tolerance, highlighting the pathogenic role of plasma
cells in AIH.32,33
It remains unclear why some patients with AIH develop no
IgG elevation despite evidence of ongoing inflammatory disease
activity. One explanation might be a shorter exposure to the
immunologic trigger of AIH, e.g. an offending drug or food
components. On the other hand, it was assumed that these
patients in general have lower IgG levels because of their genetic
predisposition,34 and therefore, show a relative elevation
considering their naturally very low IgG. Along with this line, it
was suggested that even in patients with normal IgG at diag-
nosis, variations of IgG could be used to monitor treatment
response.2 In support of this assumption, we observed a signif-
icant fall of IgG (−22%) upon immunosuppression, and a decrease
of IgG, sometimes below the limit of normal, was observed in
virtually all patients. Moreover, IgG levels remained significantly
lower in the normal IgG group throughout the study. Nonethe-
less, the fall of IgG might not be related to disease activity, but to
an unspecific effect of immunosuppressive treatment.35 For
instance, IgG and IgA decreased to the same extent under
immunosuppression in the normal IgG group. Hence, it remains
unclear whether variations of IgG can be used as a surrogate
marker of disease activity in patients with normal IgG at diag-
nosis. An assessment of histological activity according to IgG
levels would be required in order to clarify this question. Of note,
IgM levels were not different between groups, consequently the
IgG/IgM ratio decreased in both study groups after initiation of
treatment.
The hypergammaglobulinemia typically seen in AIH is
considered to be attributable to increased IgG. Contrary to this
assumption, our findings suggest that IgA also contributes to the
hypergammaglobulinemia in typical AIH: most patients with
active AIH had IgA within the upper limit of normal or slightly
elevated IgA. In addition, IgA was higher in patients in the typical
AIH group than in those with normal IgG at diagnosis. IgA is a
crucial factor in mucosal immunity and the predominant anti-
body class in mucosal surfaces.36 Therefore, our findings on IgA
might be seen in context with the emerging data linking alter-
ations of gut microbiota (dysbiosis) and increased intestinal
permeability with experimental and human AIH.37–39
Besides increased IgG and gamma-globulins, autoantibodies
are a serological hallmark of AIH and are a crucial part of diag-
nostic scores. ANA and SMA antibodies were slightly less
frequently detected in patients with normal IgG than in the
control group. Presumably the detection of autoantibodies has
been missed in some patients with low IgG, since antibody titres
were not corrected for IgG. Likewise, patients with typical AIH
had higher autoantibody titres, however, not when controlled for6vol. 2 j 100094
the higher IgG levels in these patients. These data indicate that
autoantibody titres and cut-offs when using ELISA testing should
be adjusted to serum IgG levels, otherwise seropositivity may be
missed in patients with low IgG.
Our study has the obvious limitations of a retrospective study
design. For instance, we could only assess the number of patients
in stable remission off treatment at last follow-up, but no in-
formation on the number of attempts to withdraw medication
was available. The participating centres are prominent referral
centres, hence a referral bias of atypical and/or more advanced
cases of AIH is possible. Moreover, patients without dependence
on immunosuppression to maintain remission and without IgG
elevation in active disease lack 2 characteristic features of AIH.
Hence, a definite diagnosis in these patients may be difficult to
obtain. In particular, the differential diagnosis between immu-
noallergic drug-induced liver injury and AIH poses a diagnostic
dilemma in these patients.
Liver histology is considered a prerequisite in the diagnostic
work-up.2 Therefore, a strength of this study may be that only
patients who had undergone a liver biopsy to establish theJHEP Reports 2020diagnosis were included. Moreover, liver specimens of 46 pa-
tients in the normal IgG group could be located and sent to a
reference pathologist for detailed re-assessment. Histological
hallmark features of AIH such as interface hepatitis, hepatocyte
rosettes and emperipolesis were observed in 93%, 91%, and 78%
of cases, respectively. Consequently, liver histology was
considered atypical for AIH in only a single patient, while it was
classified as typical (76%) or compatible (22%) in all others
(Fig. 2). Moreover, to further assure a valid diagnosis of AIH in
patients with normal IgG, a crude assessment of the revised
diagnostic criteria from 1999 were applied,18 and all patients
reached a score corresponding to at least a probable diagnosis
of AIH.
In conclusion, compared to patients with typical AIH, pa-
tients with normal IgG at diagnosis, show strikingly similar
biochemical, serological and histological features as well as
comparable treatment responses, but might represent a sub-
group with a higher chance of successful drug withdrawal.
Serum IgG levels might be used as a predictor of hepatic im-
mune tolerance.Abbreviations
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